<p>多伦多 --（商业资讯）--Cybin Inc.（纽约证券交易所美国：CYBN）（Cboe CA：CYBN）是一家临床阶段的突破性制药公司，致力于通过开发创新的下一代治疗方案来彻底改变心理健康护理。今天宣布将自愿将其美国股票交易所上市从纽约证券交易所美国（NYSE American LLC）转移至纳斯达克全球市场（“纳斯达克”）。公司预计其普通股将在 2026 年 1 月 2 日市场收盘时停止在纽约证券交易所美国交易，并将在 2026 年 1 月 5 日市场开盘时开始在纳斯达克交易。</p>
<p>与在纳斯达克开始交易同时，公司将以 Helus Pharma（发音为 “Heal Us”）的名义开展业务。它将不再以 “CYBN” 作为股票代码，而是将以 “HELP” 作为股票代码进行交易。公司将继续在 Cboe Canada 上市，并将在 2026 年 1 月 5 日开始以新的 “HELP” 股票代码进行交易。</p>
<p>“我们很高兴加入在纳斯达克上市的全球制药公司社区，并感谢纽约证券交易所美国在过去四年中对公司的支持，” Cybin 的临时首席执行官 Eric So 表示。“转移到纳斯达克标志着 Cybin 向全球制药公司演变的下一步。”</p>
<p><strong>关于 Cybin</strong></p>
<p>Cybin 是一家临床阶段的突破性制药公司，致力于通过开发新的和创新的下一代治疗方案来彻底改变心理健康护理，以满足那些遭受心理健康问题的人们的巨大未满足需求。</p>
<p>凭借有前景的领先数据，Cybin 正在通过引入新型药物来改变心理健康治疗领域，这些药物为患者提供有效和持久的结果。公司目前正在开发 CYB003，处于针对重度抑郁症的辅助治疗的第三阶段研究中，该药物已获得美国食品药品监督管理局的突破性疗法认定，以及 CYB004，处于针对广泛性焦虑症的第二阶段研究中。Cybin 还拥有一系列广泛的研究管道，涉及多种研究性化合物。</p>
<p>Cybin 成立于 2019 年，在加拿大、美国、英国和爱尔兰开展业务。有关公司的最新信息和更多了解，请访问 www.cybin.com 或在 X、LinkedIn、YouTube 和 Instagram 上关注团队。</p>
<p><strong>警示性说明和前瞻性声明</strong></p>
<p>本新闻稿中与公司相关的某些声明属于前瞻性声明或前瞻性信息，根据适用的证券法（统称为 “前瞻性声明”）的定义，具有前瞻性特征。前瞻性声明不是基于历史事实，而是基于对未来事件的当前预期和预测，因此受到风险和不确定性的影响，这可能导致实际结果与前瞻性声明所表达或暗示的未来结果有实质性差异。这些声明通常可以通过使用 “可能”、“应该”、“能够”、“潜在”、“可能”、“打算”、“估计”、“计划”、“预期”、“相信” 或 “继续” 等前瞻性词汇，或其否定形式或类似变体来识别。本新闻稿中的前瞻性声明包括关于公司预期在纳斯达克开始交易和停止在纽约证券交易所美国交易的声明；以及公司计划开发专有药物发现平台、创新药物递送系统、新型制剂方法和心理健康治疗方案的声明。</p>
<p>这些前瞻性声明基于公司管理层在作出这些声明时的合理假设和估计。实际未来结果可能会有实质性差异，因为前瞻性声明涉及已知和未知的风险、不确定性以及其他因素，这可能导致公司的实际结果、表现或成就与任何前瞻性声明所表达或暗示的未来结果、表现或成就有实质性差异。这些因素包括但不限于：一般宏观经济条件的波动；证券市场的波动；对迷幻药市场规模的预期；公司成功实现其商业目标的能力；增长计划；政治、社会和环境的不确定性；员工关系；可能在公司运营市场中施加限制的法律和法规的存在；疾病爆发对公司运营的影响；以及在公司截至 2025 年 9 月 30 日的三个月和六个月期间的管理讨论与分析中列出的风险因素，以及公司截至 2025 年 3 月 31 日的年度信息表，这些信息可在公司的 SEDAR+ 档案中找到，网址为 www.sedarplus.ca，以及在美国证券交易委员会的 EDGAR 上，网址为 www.sec.gov/edgar。尽管本新闻稿中包含的前瞻性声明是基于公司管理层当时认为合理的假设，但公司无法向股东保证实际结果将与这些前瞻性声明一致，因为可能还有其他因素导致结果未如预期、估计或意图。读者不应对本新闻稿中包含的前瞻性声明过度依赖。除非法律要求，公司不承担更新前瞻性声明的义务，包括信念、观点、预测或其他因素的变化。</p>
<p>公司对其拟议产品不作任何医疗、治疗或健康益处的声明。美国食品药品监督管理局、加拿大卫生部或其他类似监管机构尚未评估关于裸盖菇素、迷幻色氨酸、色氨酸衍生物或其他迷幻化合物的声明。这些产品的有效性尚未通过批准的研究确认。无法保证使用裸盖菇素、迷幻色氨酸、色氨酸衍生物或其他迷幻化合物能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。如果 Helis 无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
<p><em>Cboe Canada 和 NYSE American LLC 证券交易所均未批准或否决本新闻稿的内容，并且对其中内容的充分性和准确性不承担责任。</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4OTE4NDlyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4OTE4NDlyMg"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218891849/en/</p>
<p><strong>投资者联系：</strong></p>
<p>Josh Barer</p>
<p>astr partners</p>
<p>董事总经理</p>
<p>(908) 578-6478</p>
<p>josh.barer@astrpartners.com</p>
<p>George Tziras</p>
<p>首席商务官</p>
<p>Cybin Inc.</p>
<p>1-866-292-4601</p>
<p>irteam@cybin.com</p>
<p><strong>媒体联系：</strong></p>
<p>Johnny Tokarczyk</p>
<p>RXMD</p>
<p>公共关系总监</p>
<p>Jtokarczyk@rxmedyn.com</p>
<p>(914) 772- 7562</p>
<p>来源：Cybin Inc.</p>

CYBN

<p>Cybin Inc.是一家临床阶段的制药公司，宣布将于 2026 年 1 月 5 日将其美国股票交易所上市从 NYSE American 转移至纳斯达克。该公司将重新品牌为 Helus Pharma，并以 “HELP” 作为股票代码。Cybin 旨在增强其在制药行业的全球影响力。该公司继续在加拿大、美国、英国和爱尔兰开展业务，专注于创新的心理健康治疗</p>

<p>TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares will cease trading on the NYSE American at market close on January 2, 2026 and commence trading on Nasdaq at market open on January 5, 2026.</p>
<div class="lb-trans"><p>多伦多 --（商业资讯）--Cybin Inc.（纽约证券交易所美国：CYBN）（Cboe CA：CYBN）是一家临床阶段的突破性制药公司，致力于通过开发创新的下一代治疗方案来彻底改变心理健康护理。今天宣布将自愿将其美国股票交易所上市从纽约证券交易所美国（NYSE American LLC）转移至纳斯达克全球市场（“纳斯达克”）。公司预计其普通股将在 2026 年 1 月 2 日市场收盘时停止在纽约证券交易所美国交易，并将在 2026 年 1 月 5 日市场开盘时开始在纳斯达克交易。</p>
</div><p>Concurrent with the commencement of trading on Nasdaq, the Company will be doing business as Helus Pharma (pronounced &#34;Heal Us&#34;). It will no longer trade under the ticker symbol “CYBN” and instead will trade under the ticker symbol “HELP”. The Company will continue to be listed on the Cboe Canada and will also trade under the new “HELP” ticker symbol commencing on January 5, 2026.</p>
<div class="lb-trans"><p>与在纳斯达克开始交易同时，公司将以 Helus Pharma（发音为 “Heal Us”）的名义开展业务。它将不再以 “CYBN” 作为股票代码，而是将以 “HELP” 作为股票代码进行交易。公司将继续在 Cboe Canada 上市，并将在 2026 年 1 月 5 日开始以新的 “HELP” 股票代码进行交易。</p>
</div><p>“We are pleased to join the community of global pharmaceutical companies listed on Nasdaq and thank the NYSE American for supporting the company over the last four years since our initial listing,” said Eric So, interim chief executive officer of Cybin. “The transfer to Nasdaq marks the next step in the evolution of Cybin into a global pharmaceutical company.”</p>
<div class="lb-trans"><p>“我们很高兴加入在纳斯达克上市的全球制药公司社区，并感谢纽约证券交易所美国在过去四年中对公司的支持，” Cybin 的临时首席执行官 Eric So 表示。“转移到纳斯达克标志着 Cybin 向全球制药公司演变的下一步。”</p>
</div><p><strong>About Cybin</strong></p>
<div class="lb-trans"><p><strong>关于 Cybin</strong></p>
</div><p>Cybin is a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.</p>
<div class="lb-trans"><p>Cybin 是一家临床阶段的突破性制药公司，致力于通过开发新的和创新的下一代治疗方案来彻底改变心理健康护理，以满足那些遭受心理健康问题的人们的巨大未满足需求。</p>
</div><p>With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004 in Phase 2 study for generalized anxiety disorder. Cybin also has an extensive research pipeline of investigational compounds.</p>
<div class="lb-trans"><p>凭借有前景的领先数据，Cybin 正在通过引入新型药物来改变心理健康治疗领域，这些药物为患者提供有效和持久的结果。公司目前正在开发 CYB003，处于针对重度抑郁症的辅助治疗的第三阶段研究中，该药物已获得美国食品药品监督管理局的突破性疗法认定，以及 CYB004，处于针对广泛性焦虑症的第二阶段研究中。Cybin 还拥有一系列广泛的研究管道，涉及多种研究性化合物。</p>
</div><p>Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.For updates and to learn more about the Company, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</p>
<div class="lb-trans"><p>Cybin 成立于 2019 年，在加拿大、美国、英国和爱尔兰开展业务。有关公司的最新信息和更多了解，请访问 www.cybin.com 或在 X、LinkedIn、YouTube 和 Instagram 上关注团队。</p>
</div><p><strong>Cautionary Notes and Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>警示性说明和前瞻性声明</strong></p>
</div><p>Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s expectations to commence trading on Nasdaq and to cease trading on the NYSE American; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.</p>
<div class="lb-trans"><p>本新闻稿中与公司相关的某些声明属于前瞻性声明或前瞻性信息，根据适用的证券法（统称为 “前瞻性声明”）的定义，具有前瞻性特征。前瞻性声明不是基于历史事实，而是基于对未来事件的当前预期和预测，因此受到风险和不确定性的影响，这可能导致实际结果与前瞻性声明所表达或暗示的未来结果有实质性差异。这些声明通常可以通过使用 “可能”、“应该”、“能够”、“潜在”、“可能”、“打算”、“估计”、“计划”、“预期”、“相信” 或 “继续” 等前瞻性词汇，或其否定形式或类似变体来识别。本新闻稿中的前瞻性声明包括关于公司预期在纳斯达克开始交易和停止在纽约证券交易所美国交易的声明；以及公司计划开发专有药物发现平台、创新药物递送系统、新型制剂方法和心理健康治疗方案的声明。</p>
</div><p>These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and six month periods ended September 30, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</p>
<div class="lb-trans"><p>这些前瞻性声明基于公司管理层在作出这些声明时的合理假设和估计。实际未来结果可能会有实质性差异，因为前瞻性声明涉及已知和未知的风险、不确定性以及其他因素，这可能导致公司的实际结果、表现或成就与任何前瞻性声明所表达或暗示的未来结果、表现或成就有实质性差异。这些因素包括但不限于：一般宏观经济条件的波动；证券市场的波动；对迷幻药市场规模的预期；公司成功实现其商业目标的能力；增长计划；政治、社会和环境的不确定性；员工关系；可能在公司运营市场中施加限制的法律和法规的存在；疾病爆发对公司运营的影响；以及在公司截至 2025 年 9 月 30 日的三个月和六个月期间的管理讨论与分析中列出的风险因素，以及公司截至 2025 年 3 月 31 日的年度信息表，这些信息可在公司的 SEDAR+ 档案中找到，网址为 www.sedarplus.ca，以及在美国证券交易委员会的 EDGAR 上，网址为 www.sec.gov/edgar。尽管本新闻稿中包含的前瞻性声明是基于公司管理层当时认为合理的假设，但公司无法向股东保证实际结果将与这些前瞻性声明一致，因为可能还有其他因素导致结果未如预期、估计或意图。读者不应对本新闻稿中包含的前瞻性声明过度依赖。除非法律要求，公司不承担更新前瞻性声明的义务，包括信念、观点、预测或其他因素的变化。</p>
</div><p>The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helis cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司对其拟议产品不作任何医疗、治疗或健康益处的声明。美国食品药品监督管理局、加拿大卫生部或其他类似监管机构尚未评估关于裸盖菇素、迷幻色氨酸、色氨酸衍生物或其他迷幻化合物的声明。这些产品的有效性尚未通过批准的研究确认。无法保证使用裸盖菇素、迷幻色氨酸、色氨酸衍生物或其他迷幻化合物能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。如果 Helis 无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
</div><p><em>Neither Cboe Canada, nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</em></p>
<div class="lb-trans"><p><em>Cboe Canada 和 NYSE American LLC 证券交易所均未批准或否决本新闻稿的内容，并且对其中内容的充分性和准确性不承担责任。</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg4OTE4NDlyMg" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218891849r2&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218891849/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218891849/en/</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Josh Barer</p>
<div class="lb-trans"><p>Josh Barer</p>
</div><p>astr partners</p>
<div class="lb-trans"><p>astr partners</p>
</div><p>Managing Director</p>
<div class="lb-trans"><p>董事总经理</p>
</div><p>(908) 578-6478</p>
<div class="lb-trans"><p>(908) 578-6478</p>
</div><p>josh.barer@astrpartners.com</p>
<div class="lb-trans"><p>josh.barer@astrpartners.com</p>
</div><p>George Tziras</p>
<div class="lb-trans"><p>George Tziras</p>
</div><p>Chief Business Officer</p>
<div class="lb-trans"><p>首席商务官</p>
</div><p>Cybin Inc.</p>
<div class="lb-trans"><p>Cybin Inc.</p>
</div><p>1-866-292-4601</p>
<div class="lb-trans"><p>1-866-292-4601</p>
</div><p>irteam@cybin.com</p>
<div class="lb-trans"><p>irteam@cybin.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>Johnny Tokarczyk</p>
<div class="lb-trans"><p>Johnny Tokarczyk</p>
</div><p>RXMD</p>
<div class="lb-trans"><p>RXMD</p>
</div><p>Public Relations Director</p>
<div class="lb-trans"><p>公共关系总监</p>
</div><p>Jtokarczyk@rxmedyn.com</p>
<div class="lb-trans"><p>Jtokarczyk@rxmedyn.com</p>
</div><p>(914) 772- 7562</p>
<div class="lb-trans"><p>(914) 772- 7562</p>
</div><p>Source: Cybin Inc.</p>
<div class="lb-trans"><p>来源：Cybin Inc.</p>
</div>

Cybin 将其美国证券交易所的上市转移至纳斯达克 | CYBN 股票新闻